昆明哪个私立医院人流好(昆明台俪妇产科官网) (今日更新中)

XIAMEN, July 23 (Xinhua) -- A rescue and breeding base for endangered Chinese white dolphins started a trial operational period on Saturday in the southeastern seaside resort of Xiamen. The base is the first of its kind in the country.The base, located on the city's Huoshaoyu Islet, includes a rescue center and a breeding area and can accommodate up to four to six white dolphins, said Pan Shijian, vice mayor of Xiamen.Previously, rescuers had to return injured white dolphins back to the sea after giving them simple medical treatment due to the lack of a rescue base, Pan said."From now on, the base will be a hospital for injured or stranded dolphins," he said.The base will also be used as a rehabilitation center for children with infantile autism and brain paralysis, with the dolphins acting as "doctors" during the children's recovery period, he added.The Chinese white dolphin mainly lives in the seas around Xiamen and the Pearl River estuary in south China. The dolphins are under first-class state protection.The Chinese Academy of Fishery Sciences estimates that about 2,000 of the dolphins are living in China's seas.

WELLINGTON, June 7 (Xinhua) -- Scientists in New Zealand have developed a new drug to fight previously untreatable hypoxic cancer tumors, which form in areas of the body starved of oxygen.The researchers at the Auckland University have entered an agreement for the clinical development of CEN-209, which was developed over 10 years of research, said a statement from the university Tuesday.CEN-209 was designed to enhance the effectiveness of radiotherapy and chemotherapy in solid hypoxic tumors, which were resistant to standard cancer therapies, said the statement. In lung cancer patients for example, about half of tumors had hypoxic regions.The new drug worked by damaging the DNA of hypoxic cancer cells, while leaving normal, healthy tissues alone.CEN-209 was designed and created by researchers at the university's Auckland Cancer Society Research Centre (ACSRC), using computer models of drug transport within tumors to accurately predict the anti-tumor activity of the drugs."Our computer models of drug transport developed in-house allowed the synthetic chemists to test their design theories and considerably shortened the discovery process," said Associate Professor Michael Hay, who led the ACSRC research chemists."CEN-209 improves markedly on previous agents in this class in terms of its ability to penetrate tumors, and this is reflected by its improved activity in the laboratory, when combined with long or short courses of radiotherapy," said researcher Professor Bill Wilson.Under the agreement between the university's Auckland UniServices Ltd. and California-based Centella Therapeutics, Inc., a subsidiary of Varian Medical Systems, Inc., Centella will have exclusive rights to CEN-209, which it will develop and trial with Cancer Research UK.The work on CEN-209 is the culmination of a program initiated with funding from the U.S. National Cancer Institute, and more recently from the Maurice Wilkins Centre for Biodiscovery. Ongoing preclinical research on CEN-209 and a backup compound was funded by grants from the Auckland Medical Research Foundation, Genesis Oncology Trust and Health Research Council of New Zealand, said the statement.

PARIS, Aug. 7 (Xinhua) -- European heavy-lift launcher Ariane 5 lifted off two communication satellites on Saturday.The Ariane 5, carrying Astra 1N and BSAT-3c/JCSAT-110R, was launched at 2252 GMT on Saturday from Kourou launch centre in French Guiana, according to live broadcast of the launching process.This was the fourth mission of Ariane 5 in 2011 and its 203th flight that sent off the two satellites Saturday night to their respective geostationary transfer orbits.Astra 1N, to be separated first, is built by EADS Astrium in Toulouse, France, for the Luxembourg-based operator SES Astra. With a designed lifespan of 15 years, it has an estimated liftoff mass of 5,350 kg and is fitted with 52 active Ku-band transponders.It is initially to deliver interim capacity from an orbital position of 28.2 degree East, and will subsequently move to SES Astra's prime location at 19.2 degree East for primary and backup services.BSAT-3c/JCSAT-110R is manufactured by Lockheed Martin Commercial Space Systems in Newtown, Pennsylvania, for Japanese operators B-SAT Corporation and SKY Perfect JSAT Corporation. This satellite weighs approximately 2,910 kg at launch time. It is to be positioned at 110 degree East longitude in geostationary orbit with a lifetime exceeding 16 years.This Ariane 5 flight has been postponed twice, firstly due to some technical problem in early July and then delayed by bad weather.Arianespace plans to achieve six Ariane 5 missions through this year.

WASHINGTON, June 20 (Xinhua) -- The U.S. Food and Drug Administration (FDA) on Monday unveiled in a report a new strategy to meet the challenges posed by rapidly rising imports of FDA- regulated products and a complex global supply chain.The report, titled "Pathway to Global Product Safety and Quality," calls on the agency to transform the way it conducts business and to act globally in order to promote and protect the health of U.S. consumers.According to the report, the FDA will partner with its counterparts worldwide to create global coalitions of regulators focused on ensuring and improving global product safety and quality. The coalitions of regulators will develop international data information systems and networks, and increase the regular and proactive sharing of data and regulatory resources across world markets.The FDA will build in additional information gathering and analysis capabilities with an increased focus on risk analytics and information technology. It increasingly will leverage the efforts of public and private third parties and industry and allocate FDA resources based on risk."FDA regulated imports have quadrupled since 2000. The FDA and our global regulatory partners recognize this new reality and realize we must work proactively and collaboratively to address the challenges we face," FDA Commissioner Margaret Hamburg said in a statement. "The FDA must further collaborate and leverage in order to close the gap between our import levels and our regulatory resources. This report is an important step in ensuring we are able to fulfill our critical public health mission."

WASHINGTON, June 20 (Xinhua) -- The U.S. Food and Drug Administration (FDA) on Monday unveiled in a report a new strategy to meet the challenges posed by rapidly rising imports of FDA- regulated products and a complex global supply chain.The report, titled "Pathway to Global Product Safety and Quality," calls on the agency to transform the way it conducts business and to act globally in order to promote and protect the health of U.S. consumers.According to the report, the FDA will partner with its counterparts worldwide to create global coalitions of regulators focused on ensuring and improving global product safety and quality. The coalitions of regulators will develop international data information systems and networks, and increase the regular and proactive sharing of data and regulatory resources across world markets.The FDA will build in additional information gathering and analysis capabilities with an increased focus on risk analytics and information technology. It increasingly will leverage the efforts of public and private third parties and industry and allocate FDA resources based on risk."FDA regulated imports have quadrupled since 2000. The FDA and our global regulatory partners recognize this new reality and realize we must work proactively and collaboratively to address the challenges we face," FDA Commissioner Margaret Hamburg said in a statement. "The FDA must further collaborate and leverage in order to close the gap between our import levels and our regulatory resources. This report is an important step in ensuring we are able to fulfill our critical public health mission."

来源：资阳报